Sanofi, GlaxoSmithKline start new COVID vaccine study

Sanofi and GlaxoSmithKline have launched a new study of their coronavirus vaccine after a previous trial produced disappointing results.

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an “insufficient” immune response to the virus in people older than 50 years.

The companies have now tweaked the vaccine’s formulation and plan to test three different dosages in the new Phase 2 study of 720…

Click here to view the original article.

Show More

Related Articles

Back to top button